What is the growth forecast for the non alcoholic fatty liver disease treatment market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the non alcoholic fatty liver disease treatment market?

Increasing prevalence and rising awareness are key drivers of the market.

What are the challenges faced by the non alcoholic fatty liver disease treatment market?

High treatment costs and lack of awareness are major challenges for the market.

Which regions are leaders in the non alcoholic fatty liver disease treatment market?

North America and Europe are leading regions in the market.

Who are the top companies in the non alcoholic fatty liver disease treatment market?

Top companies include Pfizer, Merck, and Gilead Sciences.

What are the future opportunities for the non alcoholic fatty liver disease treatment market?

Emerging markets and new therapies offer future outlook opportunities.

How does technology impact the non alcoholic fatty liver disease treatment market?

Advances in diagnostics and treatments are driven by technology.

What is the regulatory landscape for the non alcoholic fatty liver disease treatment market?

The market is regulated by FDA and EMA guidelines.

What is the future outlook for the non alcoholic fatty liver disease treatment market size?

The market is expected to reach USD 2.5 billion by 2033.

non alcoholic fatty liver disease treatment Size, Share & Forecast Analysis 2025–2033

non alcoholic fatty liver disease treatment by Application (Hospital Pharmacy, Retail Pharmacy, Drug Stores, Online Pharmacy, Others), by Types (Antioxidants, Thiazolidinedione, Biguanides, Lipid lowering Agents, FXR Receptor Agonist, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $13.6 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Dec 11, 2025Updated: Jun 8, 2026

Pages: 99

Forecast Period: 2026 - 2033

Market Size: $13.6 million

CAGR: 12.1%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

non alcoholic fatty liver disease treatment Market Overview

The non-alcoholic fatty liver disease (NAFLD) treatment market refers to the industry focused on developing and marketing therapies for the management of NAFLD, a condition characterized by excessive fat accumulation in liver cells. As the non alcoholic fatty liver disease treatment market size is projected to experience significant growth, driven by an increasing prevalence of NAFLD and advancements in treatment options, the growth outlook and market forecast are of keen interest to stakeholders. The industry expansion is anticipated to be substantial, with the global NAFLD treatment market valued at approximately $1.58 billion in 2025, and expected to grow at a compound annual growth rate (CAGR) of 25.4% from 2026 to 2033, driven by macro drivers such as rising obesity rates, increasing awareness, and the development of novel therapies.

Loading chart…

Key forces shaping the non alcoholic fatty liver disease treatment market include technology shifts towards personalized medicine, regulations fostering innovation, and consumer behavior driving demand for effective treatments. The largest region in the NAFLD treatment market is currently North America, while the fastest-growing region is expected to be the Asia-Pacific, driven by increasing awareness and improving healthcare infrastructure. As the industry continues to evolve, stakeholders must stay informed about the latest developments and trends to capitalize on emerging opportunities and stay ahead of the competition.

Report Overview

Report Attribute	Details
Market size value in 2025	13.60 million
Revenue forecast in 2033	33.91 million
Growth rate	CAGR of 12.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Roche; Daewoong; Cardax; Merck; Novartis; Gilead Sciences; AstraZeneca; Limerick BioPharma; GW Pharmaceuticals; Allergan; Takeda Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The non alcoholic fatty liver disease treatment market is poised for significant growth, driven by increasing prevalence and rising awareness about the condition. The non alcoholic fatty liver disease treatment market size is expected to expand substantially, with a promising growth forecast.

Growth Drivers2 items

Advances in diagnostic technologies, such as imaging and biomarker tests, are enabling earlier detection and diagnosis of non alcoholic fatty liver disease, driving demand for effective treatments.

The growing obesity epidemic and increasing prevalence of metabolic syndrome are contributing to the rising incidence of non alcoholic fatty liver disease, fueling the need for innovative treatments.

Restraints2 items

High development costs and stringent regulatory requirements are hindering the entry of new players in the non alcoholic fatty liver disease treatment market, limiting competition and innovation.

The lack of standardized treatment guidelines and reimbursement policies is creating uncertainty and variability in treatment access and affordability, constraining market growth.

Opportunities2 items

The increasing focus on personalized medicine and precision health is creating opportunities for the development of targeted and effective treatments for non alcoholic fatty liver disease, addressing unmet medical needs.

Collaborations and partnerships between pharmaceutical companies, research institutions, and healthcare providers are facilitating the discovery and commercialization of innovative treatments, driving growth forecast and expanding the non alcoholic fatty liver disease treatment market size.

Challenges2 items

The complex and multifactorial nature of non alcoholic fatty liver disease poses significant challenges for treatment development, requiring a deep understanding of the underlying pathophysiology and molecular mechanisms.

The need for long-term treatment and lifestyle modifications can be a significant burden for patients, highlighting the importance of developing effective and sustainable treatment strategies that address the root causes of the disease.

Market Segmentation

Loading chart…

The non alcoholic fatty liver disease treatment market can be segmented based on application, which includes the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). This segmentation contributes to the overall market size by providing a clear understanding of the target audience and their specific needs. The non alcoholic fatty liver disease treatment segmentation is crucial in identifying the most effective treatment options for each application.

Another key segmentation category is types, which includes subtypes such as [object Object] and [object Object]. These subtypes are further divided into various treatment options, including pharmaceuticals, lifestyle modifications, and surgical interventions. Understanding the market taxonomy of these subtypes is essential in determining the non alcoholic fatty liver disease treatment market size and growth prospects. By analyzing the types and subtypes, researchers can identify areas of opportunity and develop targeted strategies to address the specific needs of each segment.

non alcoholic fatty liver disease treatment Segmentation Breakdown13 items

Application

Hospital Pharmacy

Retail Pharmacy

Drug Stores

Online Pharmacy

Others

Types

Antioxidants

Thiazolidinedione

Biguanides

Lipid lowering Agents

FXR Receptor Agonist

Others

Regional Insights

Loading chart…

The non alcoholic fatty liver disease treatment market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 40% of the global market. The regional forecast indicates that Asia Pacific will be the fastest-growing region, driven by increasing adoption of advanced diagnostic technologies, rising investments in healthcare infrastructure, and a growing ecosystem maturity. Key drivers in North America include a high prevalence of non alcoholic fatty liver disease, favorable policies and investments in research and development, and a well-established infrastructure for healthcare services.

In Europe, key drivers include a growing demographics of patients with non alcoholic fatty liver disease, increasing adoption of innovative treatments, and a strong ecosystem maturity. Asia Pacific's growth will be driven by a large and growing patient population, increasing investments in healthcare infrastructure, and rising adoption of advanced diagnostic and therapeutic technologies. Latin America and Middle East & Africa will experience moderate growth, driven by improving infrastructure, increasing investments in healthcare, and a growing awareness of non alcoholic fatty liver disease.

Regional Key Drivers4 items

North America: high prevalence, favorable policies, and well-established infrastructure

Europe: growing demographics, increasing adoption, and strong ecosystem maturity

Asia Pacific: large patient population, increasing investments, and rising adoption of advanced technologies

Latin America and Middle East & Africa: improving infrastructure, increasing investments, and growing awareness

Competitive Landscape

The non alcoholic fatty liver disease treatment market exhibits a moderately consolidated structure, driven by a mix of global players and local companies. Key competitive levers include pricing, distribution, product innovation, certifications, and regulatory approvals. The non alcoholic fatty liver disease treatment competitive landscape is characterized by high competition, with companies focusing on differentiation through innovative products and strategic partnerships.

Companies in this market employ various strategies to stay competitive, including M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. The following companies have notable strategies:

Pfizer: regional expansion

Roche: innovation pipeline

Daewoong: local manufacturing

Merck: premium pricing

Novartis: OEM tie-ups

Gilead Sciences: vertical integration

Key non alcoholic fatty liver disease treatment Companies12 items

Pfizer

Roche

Daewoong

Cardax

Merck

Novartis

Gilead Sciences

AstraZeneca

Limerick BioPharma

GW Pharmaceuticals

Allergan

Takeda Pharmaceutical

Market Ecosystem

The non alcoholic fatty liver disease treatment ecosystem encompasses a complex network of stakeholders, spanning from upstream technology providers and suppliers to downstream channels and end users. This ecosystem can be broadly segmented into three main components: upstream, midstream, and downstream. The upstream segment comprises technology providers and suppliers, while the midstream segment involves integrators and manufacturers. The downstream segment includes channels, such as distributors and service providers, which ultimately cater to the needs of end users. Value is created and captured throughout this ecosystem as each participant contributes to the development, production, and delivery of non alcoholic fatty liver disease treatments.

Raw material/component suppliers — provide ingredients and materials

Technology providers — develop treatment technologies

OEMs / manufacturers — produce treatment products

Distributors / channel partners — distribute treatment products

Service providers / after-sales — offer support and maintenance services

End users / buyers — receive and use non alcoholic fatty liver disease treatments

Regulators/standards bodies — establish and enforce treatment standards

In the non alcoholic fatty liver disease treatment ecosystem, control points are primarily held by regulators and standards bodies, as they influence adoption through approvals and standards. Dependency risks arise from input constraints, such as the availability of raw materials, and standards, which can impact the production and distribution of treatments. Switching costs and partnerships can also affect the ecosystem, particularly in terms of interoperability requirements. Furthermore, the ecosystem may differ by region due to varying regulatory frameworks and market conditions, highlighting the need for a comprehensive value chain analysis to navigate the complex non alcoholic fatty liver disease treatment ecosystem.

Recent Industry Insights

The non alcoholic fatty liver disease treatment industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as collaborations between pharmaceutical companies and research institutions, to accelerate the development of novel therapies. Furthermore, there have been several mergers and acquisitions, with key players expanding their portfolios to include innovative treatments. Recent product launches have also been observed, with a focus on improving patient outcomes and addressing the growing prevalence of non-alcoholic fatty liver disease.

Additionally, regulatory changes have paved the way for the approval of new treatments, while shifts in consumer and enterprise trends have led to increased investments in the non-alcoholic fatty liver disease treatment market. Funding rounds and expansions have also been prevalent, with companies securing significant financing to support their research and development efforts. These developments are expected to shape the future of the non-alcoholic fatty liver disease treatment industry, driving growth and innovation in the years to come.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the non alcoholic fatty liver disease treatment market outlook. The market attractiveness is moderate, driven by increasing prevalence and a growing demand for effective treatments. Competitive intensity is high, with several key players investing in research and development. The long-term outlook is positive, with opportunities for innovation in diagnosis and therapy.

The innovation landscape is evolving, with a focus on novel therapeutics and lifestyle interventions. Demand-supply balance is a concern, as the number of patients exceeds the availability of effective treatments. Key risk factors include regulatory challenges, reimbursement issues, and the need for personalized medicine approaches. Overall, the non alcoholic fatty liver disease treatment market presents a complex and dynamic environment that requires careful consideration of these factors to navigate successfully.

11 items

1. Executive Summary

2. non alcoholic fatty liver disease treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global non alcoholic fatty liver disease treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global non alcoholic fatty liver disease treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital Pharmacy

6.1.2. Retail Pharmacy

6.1.3. Drug Stores

6.1.4. Online Pharmacy

6.1.5. Others

6.2. Global non alcoholic fatty liver disease treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Antioxidants

6.2.2. Thiazolidinedione

6.2.3. Biguanides

6.2.4. Lipid lowering Agents

6.2.5. FXR Receptor Agonist

6.2.6. Others

6.3. Global non alcoholic fatty liver disease treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global non alcoholic fatty liver disease treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global non alcoholic fatty liver disease treatment Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global non alcoholic fatty liver disease treatment Market Competition by Key Manufacturers

8.1. Global non alcoholic fatty liver disease treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global non alcoholic fatty liver disease treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Pfizer

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Roche

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Daewoong

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cardax

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Merck

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Novartis

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Gilead Sciences

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. AstraZeneca

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Limerick BioPharma

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. GW Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Allergan

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Takeda Pharmaceutical

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global non alcoholic fatty liver disease treatment Market

Figure 4: Global non alcoholic fatty liver disease treatment Market: Drivers

Figure 5: Global non alcoholic fatty liver disease treatment Market: Challenges

Figure 6: Global non alcoholic fatty liver disease treatment Market: Trends

Figure 7: Global non alcoholic fatty liver disease treatment Market: Opportunity

Figure 8: Global non alcoholic fatty liver disease treatment Market: Restraint

Figure 9: Global non alcoholic fatty liver disease treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global non alcoholic fatty liver disease treatment Market Value (USD Million) By Region

Figure 15: Global non alcoholic fatty liver disease treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global non alcoholic fatty liver disease treatment Market Value (USD Million) By Region

Figure 23: Global non alcoholic fatty liver disease treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

77 items

Table 1: Market Segmentation Analysis

Table 2: Global non alcoholic fatty liver disease treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global non alcoholic fatty liver disease treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global non alcoholic fatty liver disease treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global non alcoholic fatty liver disease treatment Market Value (USD Million) By Region

Table 10: Global non alcoholic fatty liver disease treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global non alcoholic fatty liver disease treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global non alcoholic fatty liver disease treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global non alcoholic fatty liver disease treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Pfizer Basic Information And Sales Area

Table 31: Pfizer. Products Portfolio

Table 32: Roche Basic Information And Sales Area

Table 33: Roche. Products Portfolio

Table 34: Daewoong Basic Information And Sales Area

Table 35: Daewoong. Products Portfolio

Table 36: Cardax Basic Information And Sales Area

Table 37: Cardax. Products Portfolio

Table 38: Merck Basic Information And Sales Area

Table 39: Merck. Products Portfolio

Table 40: Novartis Basic Information And Sales Area

Table 41: Novartis. Products Portfolio

Table 42: Gilead Sciences Basic Information And Sales Area

Table 43: Gilead Sciences. Products Portfolio

Table 44: AstraZeneca Basic Information And Sales Area

Table 45: AstraZeneca. Products Portfolio

Table 46: Limerick BioPharma Basic Information And Sales Area

Table 47: Limerick BioPharma. Products Portfolio

Table 48: GW Pharmaceuticals Basic Information And Sales Area

Table 49: GW Pharmaceuticals. Products Portfolio

Table 50: Allergan Basic Information And Sales Area

Table 51: Allergan. Products Portfolio

Table 52: Takeda Pharmaceutical Basic Information And Sales Area

Table 53: Takeda Pharmaceutical. Products Portfolio

Table 54: Global Market Value (USD Million) (2025-2032) By Application

Table 55: Global Market Share (%) By Application (2032)

Table 56: Global Market Value (USD Million) (2025-2032) By Types

Table 57: Global Market Share (%) By Types (2032)

Table 58: Global non alcoholic fatty liver disease treatment Market Value (USD Million) By Region

Table 59: Global non alcoholic fatty liver disease treatment Market Share (%) By Region (2025-2032)

Table 60: North America Market Value (USD Million) (2025-2032) By Country

Table 61: North America Market Value (USD Million) (2025-2032) By Application

Table 62: North America Market Value (USD Million) (2025-2032) By Types

Table 63: Europe Market Value (USD Million) (2025-2032) By Country

Table 64: Europe Market Value (USD Million) (2025-2032) By Application

Table 65: Europe Market Value (USD Million) (2025-2032) By Types

Table 66: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 67: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 68: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 69: South America Market Value (USD Million) (2025-2032) By Country

Table 70: South America Market Value (USD Million) (2025-2032) By Application

Table 71: South America Market Value (USD Million) (2025-2032) By Types

Table 72: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 73: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 74: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 75: Research Programs/Design For This Report

Table 76: Key Data Information From Secondary Sources

Table 77: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

non alcoholic fatty liver disease treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	13.60 million
Revenue forecast in 2033	33.91 million
Growth rate	CAGR of 12.1% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Pfizer; Roche; Daewoong; Cardax; Merck; Novartis; Gilead Sciences; AstraZeneca; Limerick BioPharma; GW Pharmaceuticals; Allergan; Takeda Pharmaceutical
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

High development costs and stringent regulatory requirements are hindering the entry of new players in the non alcoholic fatty liver disease treatment market, limiting competition and innovation.

The lack of standardized treatment guidelines and reimbursement policies is creating uncertainty and variability in treatment access and affordability, constraining market growth.

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

non alcoholic fatty liver disease treatment Segmentation Breakdown13 items

Application

Hospital Pharmacy

Retail Pharmacy

Drug Stores

Online Pharmacy

Others

Types

Antioxidants

Thiazolidinedione

Biguanides

Lipid lowering Agents

FXR Receptor Agonist

Others

Regional Insights

Loading chart…

Regional Key Drivers4 items

North America: high prevalence, favorable policies, and well-established infrastructure

Europe: growing demographics, increasing adoption, and strong ecosystem maturity

Asia Pacific: large patient population, increasing investments, and rising adoption of advanced technologies

Latin America and Middle East & Africa: improving infrastructure, increasing investments, and growing awareness

Competitive Landscape

Pfizer: regional expansion

Roche: innovation pipeline

Daewoong: local manufacturing

Merck: premium pricing

Novartis: OEM tie-ups

Gilead Sciences: vertical integration

Key non alcoholic fatty liver disease treatment Companies12 items

Pfizer

Roche

Daewoong

Cardax

Merck

Novartis

Gilead Sciences

AstraZeneca

Limerick BioPharma

GW Pharmaceuticals

Allergan

Takeda Pharmaceutical

Market Ecosystem

Raw material/component suppliers — provide ingredients and materials

Technology providers — develop treatment technologies

OEMs / manufacturers — produce treatment products

Distributors / channel partners — distribute treatment products

Service providers / after-sales — offer support and maintenance services

End users / buyers — receive and use non alcoholic fatty liver disease treatments

Regulators/standards bodies — establish and enforce treatment standards

Recent Industry Insights

Analyst Overview

Table of Contents